The clinical utility of the cancer chemotherapeutic agent doxorubicin (DOX) is limited by its cardiotoxicity. Doxorubicinol (DOXol), the major biometabolite of DOX, preferentially accumulates in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback